Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 4, 2008, Pages 1500-1502

  Chaturvedi, Vishnu ^a   Ramani, Rama ^a   Ghannoum, Mahmoud A ^b   Killian, Scott B ^c   Holliday, Nicole ^c   Knapp, Cindy ^c   Ostrosky Zeichner, Luis ^d   Messer, Shawn A ^e   Pfaller, Michael A ^e   Iqbal, Naureen J ^f   Arthington Skaggs, Beth A ^f   Vazquez, Jose A ^g   Sein, Tin ^h   Rex, John H ⁱ   Walsh, Thomas J ^h  

^a WADSWORTH CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Trek Diagnostic Systems   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g WAYNE STATE UNIVERSITY   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA KRUSEI; CONCENTRATION RESPONSE; DRUG INHIBITION; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; REPRODUCIBILITY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; DRUG THERAPY, COMBINATION; ECHINOCANDINS; HUMANS; LABORATORIES; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; QUALITY CONTROL; TRIAZOLES;

EID: 42049112162     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00574-07     Document Type: Article

References (18)

1. Canton, E., J. Peman, M. Gobernado, A. Viudes, and A. Espinel-Ingroff. 2005. Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob. Agents Chemother. 49:1593-1596.
2. Cuenca-Estrella, M. 2004. Combinations of antifungal agents in therapy - what value are they? J. Antimicrob. Chemother. 54:854-869.
3. Forrest, G. 2006. Role of antifungal susceptibility testing in patient management. Curr. Opin. Infect. Dis. 19:538-543.
4. Howden, B. P., M. A. Slavin, A. P. Schwarer, and A. M. Mijch. 2003. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur. J. Clin. Microbiol. Infect. Dis. 22:111-113.
5. Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
6. Kauffman, C. A. 2006. Clinical efficacy of new antifungal agents. Curr. Opin. Microbiol. 9:483-488.
7. Klepser, M. E., E. J. Ernst, R. E. Lewis, M. E. Ernst, and M. A. Pfaller. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42:1207-1212.
8. Lewis, R. E., D. J. Diekema, S. A. Messer, M. A. Pfaller, and M. E. Klepser. 2002. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J. Antimicrob. Chemother. 49:345-351.
9. Meletiadis, J., P. E. Verweij, D. T. TeDorsthorst, J. F. Meis, and J. W. Mouton. 2005. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med. Mycol. 43:133-152.
10. Moody, J. A. 1991. Synergism testing. Broth microdilution checkerboard and broth macrodilution methods, p. 5.18.1-5.18.28. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook, vol. 1. American Society for Microbiology, Washington, DC.
11. NCCLS/CLSI. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. M27-A2, 2nd ed. National Committee for Clinical Laboratory Standards/Clinical Laboratory Standards Institute, Wayne, PA.
12. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
13. Ostrosky-Zeichner, L., D. Kontoyiannis, J. Raffalli, K. M. Mullane, J. Vazquez, E. J. Anaissie, J. Lipton, P. Jacobs, J. H. van Rensburg, J. H. Rex, W. Lau, D. Facklam, and D. N. Buell. 2005. International, open-label, non-comparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis. 24:654-661.
14. Park, D., J. Sohn, H. Cheong, W. Kim, M. Ja Kim, J. H. Kim, and C. Shin. 2006. Combination therapy of disseminated coccidioidomycosis with caspofungin and fluconazole. BMC Infect.Dis. 6:26.
15. Rex, J. H., P. G. Pappas, A. W. Karchmer, J. Sobel, J. E. Edwards, S. Hadley, C. Brass, J. A. Vazquez, S. W. Chapman, H. W. Horowitz, M. Zervos, D. McKinsey, J. Lee, T. Babinchak, R. W. Bradsher, J. D. Cleary, D. M. Cohen, L. Danziger, M. Goldman, J. Goodman, E. Hilton, N. E. Hyslop, D. H. Kett, J. Lutz, R. H. Rubin, W. M. Scheld, M. Schuster, B. Simmons, D. K. Stein, R. G. Washburn, L. Mautner, T. C. Chu, H. Panzer, R. B. Rosenstein, and J. Booth. 2003. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36:1221-1228.
16. Roling, E. E., M. E. Klepser, A. Wasson, R. E. Lewis, E. J. Ernst, and M. A. Pfaller. 2002. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn. Microbiol. Infect. Dis. 43:13-17.
17. Spanakis, E. K., G. Aperis, and E. Mylonakis. 2006. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin. Infect. Dis. 43:1060-1068.
18. Ustun, C., G. Huls, M. Stevart, and K. A. Marr. 2006. Resistant Microascus cinosus pneumonia can be treated with a combination of surgery, multiple anti-fungal agents and a growth factor. Mycopathologia 162:299-302.